Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Advanced colorectal cancer Age: Adult Condition: Day 1 |
Dose: Intravenous – Oxaliplatin 85 mg/m² + leucovorin 200 mg/m² followed by 5-fluorouracil 400 mg/m² bolus then 5-fluorouracil 600 mg/m² infusion Frequency: repeat every 2 weeks Note: Oxaliplatin and leucovorin infused over 2 hours; 5-fluorouracil bolus over 2-4 minutes; 5-fluorouracil infusion in 5% dextrose injection (500 mL) over 22 hours |
|
Indication: Advanced colorectal cancer Age: Adult Condition: Day 2 |
Dose: Intravenous – Leucovorin 200 mg/m² followed by 5-fluorouracil 400 mg/m² bolus then 5-fluorouracil 600 mg/m² infusion Frequency: repeat every 2 weeks Note: Regimen without oxaliplatin; leucovorin infused over 2 hours; 5-fluorouracil bolus over 2-4 minutes; 5-fluorouracil infusion in 5% dextrose injection (500 mL) over 22 hours |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Tablet – Safety and efficacy not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment Mild (Creatinine Clearance 50-80 mL/minute) |
Dose: Not specified Note: No dosage adjustment required. Exposure of unbound platinum tends to increase in renally impaired patients |
|
Condition: Renal Impairment Moderate (Creatinine Clearance 30-49 mL/minute) |
Dose: Not specified Note: No dosage adjustment required. Exposure of unbound platinum tends to increase in renally impaired patients |
Administration
- For IV use only
- Must be diluted before use
Side Effect
- Peripheral neuropathy (76%)
- Anemia (64%)
- Nausea (64%)
- Fatigue (61%)
- Diarrhea (46%)
- Vomiting (37%)
- Abdominal pain (31%)
- Constipation (31%)
- Thrombocytopenia (30%)
- Fever (25%)
- Anorexia (20%)
- Leukopenia (13%)
- Dyspnea (13%)
- Cough (11%)
- Edema (10%)
- Neutropenia (7%)
- Pharyngolaryngeal dysesthesia (1-2%)
- Pulmonary fibrosis
- Posterior leukoencephalopathy syndrome
- Anaphylactic-like reaction (uncommon)
- Pulmonary fibrosis (uncommon)
- Anaphylaxis
- pulmonary fibrosis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Digoxin
|
May decrease plasma levels
|
|
Nephrotoxic drugs
|
May increase risk of toxicity
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Peripheral Neuropathy
|
Can worsen nerve damage
|
|
Severe Renal Impairment
|
Risk of toxicity
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store intact vials at 15-30°C; do not freeze. Reconstituted solution: May store at 2-8°C for up to 24 hr. Diluted solutions: Stable up to 6 hr at 20-25°C or up to 24 hr under refrigeration at 2-8°C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.